Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.
Atherosclerosis. 2019 Jul;286:1-6. doi: 10.1016/j.atherosclerosis.2019.04.222. Epub 2019 Apr 20.
The recently identified adiponectin paralogue C1q and tumor necrosis factor-related protein 1 (CTRP1) has been associated with obesity-linked disorders and coronary atherosclerosis. So far, the impact of circulating CTRP1 on the incidence of future cardiovascular events is unclear. Therefore, we aimed at investigating the association between CTRP1 and future cardiovascular risk.
We measured CTRP1 serum levels in 539 patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD). Prospectively, we recorded major adverse cardiovascular events (MACE), defined as the incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke over a follow-up period of 8 years.
At baseline, obesity, the metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease were significantly associated with increased CTRP1 (all p-values ≤0.001). Prospectively, MACE rates were lowest in the first quartile (15.3%) and increased over the second (23.7%) to the third and fourth quartile (each 29.0%; p = 0.008). Moreover, after multivariable adjustment, CTRP1 was significantly associated with future MACE, with adjusted HRs of 1.83 [1.04-3.23]; p=0.037, 2.16 [1.25-3.75]; p=0.006, and 1.80 [1.03-3.15]; p=0.038, for CTRP1 quartiles two, three and four, respectively, when compared to quartile one.
We conclude that high serum levels of CTRP1 are significantly associated with future MACE.
最近发现的脂联素类似物 C1q 和肿瘤坏死因子相关蛋白 1（CTRP1）与肥胖相关疾病和冠状动脉粥样硬化有关。到目前为止，循环 CTRP1 对未来心血管事件发生的影响尚不清楚。因此，我们旨在研究 CTRP1 与未来心血管风险之间的关系。
我们测量了 539 例因确诊或疑似稳定型冠状动脉疾病（CAD）而行冠状动脉造影的患者的血清 CTRP1 水平。前瞻性地，我们记录了主要不良心血管事件（MACE），定义为 8 年随访期间心血管死亡、非致死性心肌梗死和非致死性卒中的发生率。
在基线时，肥胖、代谢综合征、2 型糖尿病和非酒精性脂肪性肝病与 CTRP1 升高显著相关（所有 p 值均≤0.001）。前瞻性地，MACE 发生率在第一四分位数（15.3%）最低，并在第二四分位数（23.7%）到第三和第四四分位数（各 29.0%；p=0.008）增加。此外，经多变量调整后，CTRP1 与未来 MACE 显著相关，调整后的 HR 分别为 1.83[1.04-3.23]；p=0.037、2.16[1.25-3.75]；p=0.006 和 1.80[1.03-3.15]；p=0.038，分别与四分位区间 2、3 和 4 相比。
我们的结论是，血清中高水平的 CTRP1 与未来 MACE 显著相关。
